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Strengths and limitations of this study
 ► This is a novel scoping review to understand what 
types of physical activity interventions exist within 
the management of bladder cancer.
 ► This review will extend the current reviews as it 
focuses on all patients with bladder cancer, both 
observational and randomised trial data, and as-
sesses evidence for potential underlying biological 
mechanisms.
 ► Stakeholders including patients, their family mem-
bers, urologists, oncologists, physiotherapists will be 
involved throughout the study.
 ► The identification and synthesis of data will also 
cover the grey literature.
 ► It is possible that our review will not include all arti-
cles which have been published in every journal as 
some may not be accessible.
AbStrACt
Introduction Patients with bladder cancer (BC) have been 
found to have worse experiences than those with other 
cancers which may partly be due to impact on quality of 
life. Currently, little is known about the impact of physical 
activity (PA) on BC outcomes. This scoping review aims 
to identify what interventions are available, their reported 
efficacy and feasibility, and a description of potential 
underlying biological mechanisms for their effects.
Methods and analysis Preferred Reporting Items 
for Systematic Reviews and Meta- Analyses Scoping 
Review (ScR) guidelines and the Levac methodology 
framework will be followed/used. Electronic databases 
will be searched (MEDLINE, EMBASE, the Cochrane 
Library, PsycInfo and Health, OpenGray). Two independent 
reviewers will screen all abstracts and titles and during 
a second stage and full- text publications for inclusion. All 
studies describing PA (as an existing lifestyle or as part 
of an intervention programme) during BC management 
will be included. Study characteristics will be recorded; 
qualitative data will be extracted and evaluated using the 
Donabedian framework. Quantitative data will be extracted 
and summarised. A further consultation step will be carried 
out with patients, their family members and healthcare 
professionals.
Ethics and dissemination Results will be disseminated 
through a peer- reviewed publication. Through the 
consultation step, we will ensure that findings will reach 
a wide audience and recommendations can be made for 
future development of PA interventions for patients with 
BC. Data used will be from publicly available secondary 
sources, and the consultation step will be carried out as 
part of patient and public involvement so this study does 
not require ethical review.
IntroduCtIon
Bladder cancer (BC) is the ninth most 
common malignancy worldwide. There are 
approximately 10 300 new BC cases diagnosed 
in the UK every year which equates to about 
28 new diagnoses every day.1 BC accounts for 
3% of all new cancer cases, and is the eighth 
most common male and 16th most common 
female cancer.2
The 2015, National Institute for for Health 
and Care Excellence (NICE) guidelines 
for BC diagnosis and management stated,3 
‘There is thought to be considerable vari-
ation across the NHS in diagnosis and 
management of BC and provision of care to 
people who have it. There is evidence that 
the patient experience for people with BC is 
worse than that for people with other cancer.’ 
The cause of the poor patient experience is 
multifactorial—but is mainly driven by the 
effects of cancer diagnosis and treatment 
on health- related quality of life (HRQoL).4 
About 30% of patients present with muscle- 
invasive BC (MIBC), although up to 45% of 
those presenting with non- muscle- invasive BC 
(NMBC) will subsequently progress to MIBC. 
Treatments for NMBC and MIBC differ, but 
both come with a variety of side effects, as 
well as invasive investigations and frequent 
follow- up due to the risk of recurrence and 
metastasis.5
Despite the burden of BC on different 
HRQoL domains,4 relatively few HRQoL 
studies have been conducted in patients with 
BC compared with other tumour groups—
so that it is also unclear how this may differ 
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between those with NMBC and MIBC.6 7 A contributing 
factor for this lack of knowledge is the small investment in 
BC research: in the UK, the total annual research spend 
on BC is only £216 per new patient compared with £561 
for prostate cancer.8
Study rAtIonAlE
Physical activity (PA) interventions have been introduced 
for cancer patients as they are thought to contribute to 
better treatment outcomes and increase HRQoL.9 More 
specifically, it has been suggested that integrating exer-
cise training with standard cancer care and treatment 
may improve disease- related physiological and psycho-
logical outcomes in patients, as it helps to reduce drug 
toxicities and increases treatment completion rates.10 
For example, an analysis by Holmes et al in the Nurses’ 
Health Study highlighted that engagement in more than 
9 MET hours/week of PA following breast- cancer diag-
nosis was inversely associated with breast cancer- specific 
mortality risk.11 A recent systematic review showed that 
the greater intensity PA interventions were associated 
with a greater beneficial effect on HRQoL which included 
the assessment of factors such as social functioning and 
fatigue.12 Several mechanisms such as enhanced immune 
response, body composition, tumour vascularisation and 
tryptophan metabolism regulation have been suggested 
to explain the potential benefits of PA interventions in 
patients with cancer.10
In contrast to some other cancers, the literature on the 
potential positive effects of PA on BC management has 
not been addressed comprehensively across the treat-
ment pathway, with currently one review focusing specif-
ically on those patients who have undergone a radical 
cystectomy which is only affecting a subgroup of patients 
with BC.13
Study objECtIvES
With this scoping review, we aim to investigate what infor-
mation is currently available on the effects of PA on the 
various stages of the BC treatment pathway. This will 
help identify the gaps in the current work on the influ-
ence of PA on BC management. We will describe types 
and duration of PA (as an existing lifestyle or as part of 
an intervention programme), the reported effects on 
clinical outcomes and HRQoL, the feasibility of PA inter-
ventions and describe the proposed biological mecha-
nisms (as this may also inform the target population and 
PA intervention design). Data from all types of available 
studies—mainly observational and randomised studies—
will ultimately help us design a PA intervention which is 
beneficial for patients with BC, but also acceptable and 
feasible for all stakeholders.
ProtoCol dESIgn
Methods for this scoping review were developed based on 
the Joanna Briggs Institute guidelines14 and more specif-
ically the methodological guidelines developed by Levac 
et al,15 which describe the below six framework stages. 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses- ScR extension for scoping reviews16 will be 
followed to ensure that all suggested items are reported.
Stage 1: identifying the research question
Through consultation with the clinical research team, the 
overall research questions are defined as:
1. What type of PA (lifestyle measurements or PA inter-
ventions) has currently been reported to affect clinical 
outcomes and/or HRQoL for patients with BC?
2. What effects of PA (interventions) on clinical out-
comes and HRQoL for BC have been reported?
3. What information is available on the feasibility of exist-
ing PA interventions?
4. Is there evidence to support underlying biological 
mechanisms for the effect of PA on BC development/
outcomes?
Stage 2: Identifying relevant studies—search strategy
The following electronic databases will be searched from 
inception until the date in which the searches will be 
performed (until November 2019): MEDLINE (using 
the PubMed interface) and Ovid Gateway (Embase and 
Ovid). The Cochrane Library and OpenGray will also be 
searched. The search strategies will be evaluated using the 
Peer Review of Electronic Search Strategies guidelines.17
Search terms have been determined through researcher 
input and researching the current available literature to 
help guide the selection of terms, ensuring they are broad 
enough to capture any PA intervention and BC study. Our 
scoping review will analyse both quantitative and quali-
tative data on PA and BC (see search strategy in online 
supplementary appendix). To ensure that all relevant 
information is retrieved, relevant grey literature sources 
will be searched.
Stage 3: study selection
Studies will be considered for inclusion if they assess clin-
ical/HRQoL outcomes in patients who have a primary 
diagnosis of BC and PA has been measured (either as 
part of their lifestyle or as part of an intervention in the 
treatment pathway). Studies will be excluded if the publi-
cation is not available in English. All papers derived from 
the digital search process will be uploaded to a reference 
management software (Endnote). From these refer-
ences, we will then document the exclusion process of 
the studies; initially excluding irrelevant studies based on 
title alone, then based on abstracts. Two review authors 
will screen the studies independently, and any lack of 
consensus will be discussed with a third review author. 
After screening titles and abstracts, the full articles will be 
read and considered for the review also by two indepen-
dent reviewers; those articles excluded will have recorded 
G
eneeskunde - P
8 / 1e V
erd. P
rotected by copyright.












pen: first published as 10.1136/bm






3Mehrotra S, et al. BMJ Open 2019;9:e033518. doi:10.1136/bmjopen-2019-033518
Open access
evidence as to why this was necessary. For studies that have 
multiple publications of the same outcome(s) reported, 
the one with the longest follow- up will be selected. If 
older publications refer to articles, those included may be 
accessed to clarify methods if needed.
Stage 4: charting the data
Two independent reviewers will conduct this process. The 
data extraction table produced will include at least the 
following headings:
1. Author.
2. Year of publication.
3. Country where the study was published/conducted.
4. Aims/purpose.
5. Study population and study size.
6. Study design (eg, observational, randomised con-
trolled trial).
7. PA type +details (eg, lifestyle, intervention).
8. Duration of intervention.
9. Outcomes.
10. Key findings that relate to scoping review objectives.
Stage 5: collating, summarising and reporting the results
For our scoping review, the studies identified will be anal-
ysed using both qualitative and quantitative methods. An 
overview of the research will be displayed through all the 
findings.
In terms of qualitative aspects, all the reported insights 
will be deductively coded into a conceptual model that 
is taken from the Donabedian conceptual framework to 
determine the advantages of PA for patients with BC.18 
This framework will be used to assess the quality of 
care and thus the effectiveness of the PA interventions 
reported through three domains: structure, process 
and outcome. By assessing interventions through three 
different domains, we will be able to identify the different 
strengths of PA interventions and use this to guide the 
design of future feasibility trials. Structure will regard the 
organisation, resources and equipment available and 
needed for the interventions. Process will evaluate how 
the intervention is implemented and the methods used 
by healthcare professionals when delivering the inter-
vention and the effect this has on the patient’s HRQoL. 
Outcome will address the overall mental state and feelings 
of patients taking part in the interventions.18
The quantitative outcomes will be assessed using informa-
tion on the following measurements:
 ► Survival or recurrence rates/response to treatment/
HRQoL measures: to inform on efficacy of the PA life-
style/intervention as well as patient selection.
 ► Adherence to the intervention: indication of practi-
cality, acceptability and feasibility of PA interventions.
Given the nature of this scoping review, we will not be 
explicitly performing a risk of bias assessment as usually 
required for quantitative systematic reviews16 because 
of the following four reasons.1 We will not compare 
the clinical outcomes of any clinical studies, but only 
describe interventions used and their potential effects.2 
Argumentative and qualitative data do not lend them-
selves to the risk of bias assessment common in quanti-
tative systematic reviews.3 We are likely to include many 
different types of studies which evaluations would have 
to be type- specific, and4 quality assessments are likely be 
very difficult to standardise between reviewers and which 
could potentially add unnecessary bias into our own 
analyses.”
Stage 6: consultation—patient and public involvement
This scoping review is a first phase in a multistage 
research programme19 aimed at developing a feasibility 
PA intervention for patients with BC. To ensure that our 
assessment of the existing evidence for the implemen-
tation of PA interventions in the BC treatment pathway 
identifies the right target population and format/timing 
of a PA intervention, we also aim to include a consulta-
tion phase in this scoping review. The results from this 
scoping review combined with the consultation phase will 
then lead to development of a PA intervention that it can 
be implemented in standard care.
This consultation phase is part of our Patient and 
Public Involvement strategy as we will work actively in 
partnership with patients, their family members and 
healthcare professionals to plan and design future PA 
interventions for patients with BC.20 More specifically, 
we will run focus groups with patients with BC and their 
families, healthcare professionals, physiotherapists and 
behavioural scientist to help identify whether the results 
of the scoping review truly reflect the needs and expec-
tations of all stakeholders involved. We will invite and 
recruit participants for this consultation phase through 
our ongoing collaborations with patient advocacy organ-
isations and healthcare professional organisations (eg, 
Action Bladder Cancer UK, Fight Bladder Cancer, British 
Association of Urological Surgeons, British Uro- Oncology 
Group).21
dISSEMInAtIon And EthICS
As outlined above, this scoping review with a consulta-
tion phase will constitute the first stage in a multistage 
research programme aimed at developing a feasibility PA 
intervention for patients with BC. Results will be dissemi-
nated through a peer- reviewed publication. Through the 
consultation step, we will ensure that findings will reach 
a wide audience and recommendations can be made for 
future development of PA interventions for patients with 
BC.
As the scoping review methodology is based on 
reviewing and collecting data from publicly available 
materials, this study does not require ethics approval. To 
facilitate knowledge translation activities, we will liaise 
with relevant stakeholders through patient advocate and 
healthcare professional organisations. This consulta-
tion step will be carried out as part of patient and public 
involvement, so this study does not require ethical review.
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